As a new type of foreign trade service provider driven by both technology commercialization and cross-border trading, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials of wild yam extract diosgenin sourced from multiple well-known original manufacturers. Possessing R&D capabilities, HiSiaddi has partnered with manufacturers on technology transformation and accurately captured market demands, repeatedly proposing formulation optimization schemes and application improvement suggestions for wild yam extract diosgenin. Below is HiSiaddi’s technical consultation case on formulation optimization for wild yam extract diosgenin. Contact HiSiaddi customer service for more formulation optimization consultation services.
Purchaser: NaturaEndo Inc., Vancouver, Canada A leading mid-to-high-end Canadian brand specializing in menopausal endocrine conditioning and premium functional dietary supplements, with products sold across national premium organic pharmacy chains, private endocrinology clinics and high-end North American wellness centers. The brand enforces five strict raw material access standards: United States Pharmacopeia (USP), Canadian HPFB food regulations, FSMA import control, EU EC396 standard for 226 pesticide residues and cGMP formulation production specifications, rejecting extracts from industrially cultivated yams and low-cost non-standard saponin raw materials.
Its core product lines include premium menopausal softgels and plant sterol composite tablets, with diosgenin as the core functional raw material in formulations. Customized requirements specify wild Dioscorea zingiberensis-sourced pharmaceutical grade diosgenin at 98.0%±0.4%, split into two customized grades: ultra-fine powder exclusive for softgels and general powder for tablets, with a fixed annual procurement volume of 19 tons and a planned new product launch cycle of 6 months.
The brand operates an independent formulation laboratory and had long imported saponin raw materials from India and Mexico. To cut procurement costs and improve raw material stability, it shifted sourcing to China for wild yam extract diosgenin in 2025. The client independently selected three domestic plant extract manufacturers for sampling and small trials, sending 11 batches of samples to authoritative Canadian third-party laboratories for testing while conducting pilot production in its own GMP formulation workshop. Five systematic technical failures emerged consecutively: fluctuating raw material component batches, powder physical defects causing filling malfunctions, formulation discoloration triggered by extract impurities, low diosgenin lipophilicity leading to substandard end-product dissolution, and residual raw material solvents destabilizing softgel shell integrity. The new product launch was delayed by 98 days, with combined losses from sample testing, auxiliary material scrapping and production line downtime equivalent to CAD 32,000. The three original suppliers could only control product content indicators and lacked end-formulation application R&D capabilities, unable to implement rectifications simultaneously across raw material production, formulation adaptation and terminal manufacturing dimensions. Upon recommendation from the Domestic Plant Extract Industry Association, Canadian NaturaEndo fully entrusted HiSiaddi Foreign Trade to set up a dedicated technical team coordinating full-chain technical delivery covering upstream raw material process improvement, midstream powder customization and modification, and downstream end-formulation optimization. Drawing on over a decade of experience in plant extract foreign trade, raw material resources, formulation application databases and a team of engineers, HiSiaddi disassembled and delivered targeted technical solutions item by item.
Original cooperating manufacturers mixed large-scale artificially cultivated Chinese yam tubers from Shaanxi with wild Qinba Dioscorea zingiberensis to reduce raw material costs. The two feedstocks feature vastly different endogenous saponin base content: wild Dioscorea zingiberensis achieves over 13% saponin conversion efficiency, while artificially cultivated Chinese yam only contains 2.8%–4.2% active ingredients without standardized separate feeding protocols, resulting in random mixing ratios per batch. Conventional open strong acid hydrolysis processes feature crude control of byproducts, leaving residual macromolecular impurities including polysaccharides, plant colloids and inorganic acid residues in finished products. Measured diosgenin purity fluctuated randomly between 96.2% and 98.9%, failing to stably meet the client’s internal labeling standard of 98.0%±0.4%, with excessive miscellaneous peaks on HPLC chromatograms violating USP raw material incoming inspection standards. The client could not design fixed active ingredient dosing ratios for formulations.
Finished powders from original manufacturers were conventionally crushed into coarse 80–100-mesh particles with wide particle size distribution, strong electrostatic adsorption and bulk density discrete values exceeding 0.18g/ml, alongside powder repose angles above 45° and extremely poor flowability. The client’s fully enclosed automatic softgel filling lines lacked supporting arch-breaking devices, leading to frequent bridging and agglomeration during raw material feeding, with equipment shutdowns for cleaning occurring 3–5 times per hour and severely compressed mass production efficiency. Single capsule filling weight errors peaked at 7.6%, far exceeding Canada’s pharmacopoeia qualified threshold of ≤3%, pushing finished product rejection rates above 28% and rendering large-scale production unfeasible. Partial batches featured powder moisture content above 1.2%, absorbing moisture and clumping in Canada’s high-humidity warehousing environment to further exacerbate filling malfunctions, despite repeated client adjustments to feeding speed and discharge caliber.
The client’s flagship menopausal tablet formulation combined diosgenin, vitamin C, zinc citrate and kudzu root extract. Trace organic acids, heavy metal ions and plant colloid impurities remaining in original saponin raw materials catalyzed accelerated oxidative degradation of vitamin C under 25°C ambient light storage stability tests. Tablets turned dark brown from pale beige after 45 days, with active ingredient attenuation rates exceeding 16%. Multiple adjustments to auxiliary material feeding sequences and replacement of antioxidant additives failed to eliminate discoloration at the source, violating the mandatory 24-month shelf-life standard required for Canadian supermarket new product filing.
Diosgenin is a highly hydrophobic monomer compound with extremely low solubility in aqueous digestive fluids. Without hydrophilic modification by original manufacturers, tablets produced per the established formulation recorded a cumulative 45-minute in-vitro dissolution rate of only 51.3% under Canadian pharmacopoeia testing methods, far below the 75% dissolution threshold required for market access. Insufficient dissolution directly reduced in-vivo absorption efficiency of the product, creating major deviations from the brand’s pre-development pharmacological test data and forming a critical technical bottleneck blocking new product launch.
Conventional single-tank strong acid hydrolysis + atmospheric ethanol extraction processes generated ethanol residues ranging from 620–750ppm, exceeding the client’s internal control limit of ≤450ppm. Residual trace organic solvents gradually penetrated and destroyed gelatin crosslink structures upon prolonged contact with softgel shells, resulting in shell softening and oil seepage after 3 months of ambient storage with high risk of full batch scrappage. Original manufacturers lacked closed rectification solvent removal equipment and could not reduce solvent residues via simple post-production drying.
HiSiaddi rapidly assembled a dedicated project team consisting of plant extract R&D engineers, Canadian dietary formulation consultants, powder scientists and CNAS-accredited third-party testing specialists. On-site inspections were conducted at Shaanxi Qinba Mountain raw material bases and cooperating GMP plant extract factories, with three verification phases (100g small samples → 50kg lab trials → 500kg pilot scale-up) implemented sequentially in combination with the client’s formulation process parameters, carrying out layered rectifications from source raw material control to end-formulation delivery.
HiSiaddi selected two agricultural cooperatives in the Qinba Mountains holding legal wild medicinal herb harvesting qualifications and signed annual exclusive directional harvesting agreements, strictly limiting harvesting of natural wild Dioscorea zingiberensis rhizomes only after frost each autumn with a complete ban on artificially cultivated Chinese yam feedstock. Each batch of raw materials is accompanied by official wild resource harvesting permits issued by local forestry authorities, field harvesting ledgers and pre-inspection pesticide residue reports. Raw materials undergo separate HPLC testing upon arrival to screen rhizome native saponin content; batches with monomer base content below 12.5% are fully rejected, eliminating finished content fluctuations stemming from mixed feedstock at the raw material stage. A three-stage gradient water washing pre-treatment process was optimized to remove surface soil, exogenous pesticide residues and water-soluble colloid impurities, reducing generation of extraction byproducts to ease subsequent purification process burdens.
The industry’s outdated open high-temperature strong acid full hydrolysis process was discarded in favor of a customized new process combining bio-enzymatic pretreatment, low-temperature two-phase hydrolysis, SMB simulated moving bed chromatographic grading purification and gradient recrystallization: ① Cellulase complex enzyme closed-wall breaking at ambient temperature gently disrupts yam cell wall structures to boost saponin conversion efficiency and avoid oxidative degradation of active ingredients induced by high temperature and strong acid; ② Segmented temperature-controlled hydrolysis locks the optimal hydrolysis temperature window at 122°C, stabilizing saponin conversion efficiency at approximately 93.5% and reducing dehydration byproduct generation; ③ Multi-stage silica gel chromatography removes colloids, organic acids and heavy metal impurities, followed by low-temperature gradient recrystallization refining. Final finished diosgenin is stably controlled between 97.9% and 98.3%, perfectly meeting the customized standard of 98.0%±0.4%. Miscellaneous peaks on HPLC chromatograms drop by over 85% with drastically reduced impurity levels, eliminating formulation discoloration triggers at the production stage. A three-stage negative pressure closed rectification system was simultaneously deployed for cyclic ethanol recovery, restricting finished solvent residues to 260–390ppm, below the client’s internal 450ppm limit to completely resolve softgel shell swelling and oil leakage issues.
Two customized powder grades were developed separately to match the client’s softgel and tablet production lines:
1. Ultra-fine powder exclusive for softgels: Low-temperature jet ultra-fine grinding + inert nitrogen closed sieving. All finished particles pass a 200-mesh sieve with powder moisture controlled ≤0.5%, optimized repose angle of 34°±2° and bulk density of 0.43–0.46g/ml, drastically reducing particle electrostatic adsorption and agglomeration probability. After powder flowability improvement, daily filling line bridging incidents fell from dozens to 0–1 per day, with capsule filling weight errors stabilized within ±1.7% and rejection rates reduced from 28% to under 1.2%.
2. General powder for tablets: Moderate graded grinding paired with inert gas homogenization balances moldability and flowability for dry compression processes, avoiding loose tablets and cracking defects. Full-process low-temperature drying under nitrogen sealing prevents powder moisture absorption and clumping during warehousing.
HiSiaddi collaborated with the client’s Canadian R&D center to adjust formulations bidirectionally via both raw material modification and auxiliary material compatibility:
1. Raw material modification: Low-temperature β-cyclodextrin inclusion modification improves dispersion solubility of hydrophobic diosgenin monomers in aqueous media without altering primary saponin content, fundamentally resolving dissolution deficiencies. Post-modification 45-minute in-vitro dissolution rose from 51.3% to 82.7%, easily clearing Canada’s pharmacopoeia dissolution threshold.
2. Formulation fine-tuning: Auxiliary material ratios and feeding sequences were optimized, removing trace acidic auxiliary materials prone to oxidation promotion and replacing partial ordinary microcrystalline cellulose with chelating calcium citrate. Calcium ions chelate residual trace heavy metals in raw materials to block heavy metal-catalyzed vitamin C oxidation reactions. Feeding procedures were adjusted: diosgenin powder and mineral auxiliary materials are pre-mixed and fed separately in batches to avoid direct contact between active ingredients and strongly reductive vitamin C. Post-improvement tablets showed no discoloration after 90 days of ambient storage, fully passing 24-month shelf-life stability testing.
HiSiaddi compiled a full English manual Diosgenin Raw Material Warehousing & Formulation Production Operation Guidelines delivering implementation details to the client’s GMP factory: raw materials stored under constant 20°C temperature, moisture-proof closed conditions with small-batch on-demand removal upon opening; softgel batching controlled at pH 4.8–5.2 with shortened ambient static storage of liquid mixtures; tablet compression workshop humidity stably regulated at 42%–48% to prevent powder moisture absorption altering physical parameters, consolidating optimization outcomes via terminal production details.
After 3 rounds of small samples and 2 rounds of pilot trial cross-border shipments, all full physical, pesticide residue and dissolution testing at Canadian third-party laboratories passed, with zero process malfunctions during 7 consecutive days of mass production trials at the client’s formulation workshop. The first combined shipment of 5.7 tons split across two grades was vacuum aluminum foil nitrogen-sealed and shipped from Shanghai Port to Vancouver, passing one-time pre-review under Canada’s HPFB customs regulations with zero inspection and smooth warehouse entry. Post raw material deployment, the client’s two new menopausal softgel and composite tablet products successfully completed Canadian pharmaceutical regulatory filing and rolled out across national premium pharmacy channels, with terminal sales exceeding brand forecasts by 22% in the first launch quarter.
Based on full delivery of technical optimization outcomes, NaturaEndo signed a yearly locked-price procurement framework of 19 tons with HiSiaddi, split into 11.2 tons of softgel ultra-fine powder and 7.8 tons of general tablet powder, scheduled for monthly production across 9 batches. In the following year, the client expanded its high-end skincare line requiring low-impurity 95% grade diosgenin, again entrusting HiSiaddi with full coordination of raw material process R&D, sample follow-up and production control. Endorsed by cooperation with this mid-to-high-end Canadian brand, HiSiaddi’s partner manufacturing factories completed technical upgrades for saponin production lines and refined a customized pharmaceutical-grade diosgenin system, subsequently securing orders from three equivalent high-end endocrine dietary brands in Australia and the Netherlands to steadily integrate domestically refined wild yam extracts into high-end North American raw material supply chains.
Reviewing the full technical service delivery process reveals a core shortcoming shared by most domestic plant extract manufacturers: exclusive focus on single active ingredient production without capacity for powder science R&D, downstream formulation compatibility adaptation or terminal production condition research. Production processes retain crude traditional extraction routes with limited systematic awareness of European and American pharmacopoeia indicators, formulation incompatibility risks and powder physical property impacts on mass production. Meanwhile, high-end European and American dietary pharmaceutical brands represented by Canada’s NaturaEndo deeply master end-formulation R&D and local regulatory and production standards yet lack research channels for China’s wild medicinal herb supply chain chaos and varying domestic plant extract process tiers. Independent direct procurement easily triggers cascading losses including raw material adulteration, production malfunctions, formulation failure and delayed new product launches.
Leveraging cross-disciplinary technical resources, HiSiaddi closed a full-chain technical loop covering upstream wild raw material traceability control → midstream extraction purification and customized powder modification → downstream formulation optimization + on-site production guidance. Acting as a neutral third-party technical service provider bridging Chinese and foreign supply and demand, HiSiaddi rectifies raw material and process defects at the production source while reverse-optimizing raw material indicators aligned with the client’s terminal dosage form characteristics, delivering one-stop resolution of full-chain technical challenges spanning raw materials to finished products. This helps high-end overseas clients avoid procurement trial-and-error costs while assisting premium domestic plant extract manufacturers to escape low-price homogeneous competition, entering the global high-end natural extract industrial chain via customized pharmaceutical-grade products.
Contact HiSiaddi customer service for more formulation optimization consultation services.
+86-13120989737 
info@hisiaddi.com 
English
